Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ArriVent BioPharma, Inc. - Common Stock (NQ: AVBP )

19.40 +0.63 (+3.36%)
Streaming Delayed Price Updated: 11:25 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,035
Open 18.85
Bid (Size) 19.15 (1)
Ask (Size) 19.51 (1)
Prev. Close 18.77
Today's Range 18.85 - 19.40
52wk Range 14.35 - 25.95
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
Via Talk Markets
AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024
AVBP stock results show that ArriVent BioPharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-3.00%
-3.00%
1 Month
+7.78%
+7.78%
3 Month
+22.01%
+22.01%
6 Month
-3.00%
-3.00%
1 Year
-3.00%
-3.00%

More News

Read More
ArriVent BioPharma Reports First Quarter 2024 Financial Results
From ArriVent BioPharma, Inc.
Via GlobeNewswire
ArriVent Appoints Kristine Peterson to its Board of Directors
From ArriVent BioPharma, Inc.
Via GlobeNewswire
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
Via Benzinga
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
Via Talk Markets
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
KKR-Backed BrightSpring Prices Below Expectations, Then Opens Lower
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.